Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry
Authors:
Open Access
- 9 March 2007
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 25 (4) , 327-334
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Epothilones in the treatment of cancerExpert Opinion on Investigational Drugs, 2006
- Mass Balance Studies, with a Focus on Anticancer DrugsClinical Pharmacokinetics, 2006
- The Binding Mode of Epothilone A on α,ß-Tubulin by Electron CrystallographyScience, 2004
- Current perspectives of 14 C-isotope measurement in biomedical accelerator mass spectrometryAnalytical and Bioanalytical Chemistry, 2004
- Phase I Trial and Pharmacokinetic Study of BMS-247550, an Epothilone B Analog, Administered Intravenously on a Daily Schedule for Five DaysJournal of Clinical Oncology, 2003
- Big physics, small doses: the use of AMS and PET in human microdosing of development drugsNature Reviews Drug Discovery, 2003
- Clinical and Preclinical Pharmacokinetics of RaltitrexedClinical Pharmacokinetics, 2000
- A Novel Application of a Pd(0)-Catalyzed Nucleophilic Substitution Reaction to the Regio- and Stereoselective Synthesis of Lactam Analogues of the Epothilone Natural ProductsJournal of the American Chemical Society, 2000
- Synthesis and Biological Evaluation of Aza-EpothilonesChemBioChem, 2000
- Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven PolymerizationJournal of Biological Chemistry, 1997